Who is sponsoring NCT02151539?

NCT02151539 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT02151539?

Interventions in NCT02151539: medical chart review, quality-of-life assessment.

What condition does NCT02151539 study?

NCT02151539 studies Graft Versus Host Disease.

Is NCT02151539 still recruiting?

NCT02151539 is currently terminated. Last updated 17 October 2019.

Last reviewed 2019-10-17 · How we verify

NCT02151539: POSTAGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

Terminated Last updated 17 October 2019

What this trial tests

trial testing medical chart review in Graft Versus Host Disease in 19 participants. Terminated before completion.

Timeline

29 August 2014

Primary endpoint
11 October 2018

11 October 2018

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	19
Start date	29 August 2014
Primary completion	11 October 2018
Estimated completion	11 October 2018
Sites	7 locations across Austria, United Kingdom, United States, Germany

Drugs / interventions tested

medical chart review
quality-of-life assessment

Conditions studied

Graft Versus Host Disease — all drugs for Graft Versus Host Disease →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, any sex, with Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research trial studies medical chart review in determining outcomes of second-line therapy in patients with acute graft-versus-host disease previously treated with extracorporeal photopheresis or other systemic therapies. Gathering information about second-line therapy in patients with acute graft-versus-host disease may help doctors learn more about the disease and find better treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
Hamilton BK. · · 2018 · cited 52× · PMID 30504315 · DOI 10.1182/asheducation-2018.1.228
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
Shaw BE. · · 2019 · cited 8× · PMID 30637541 · DOI 10.1007/s11899-019-0494-x

Verify or expand the search:

Other trials of medical chart review

Trials testing the same drug.

NCT04000061 — Heart Failure-USB: Prediction and Progression · recruiting
NCT01567722 — Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · terminated
NCT01381705 — Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma · completed
NCT01192750 — Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Pre · completed
NCT01145469 — Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Ther · completed

Other recruiting trials for Graft Versus Host Disease

Currently open trials in the same condition.

NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT06705062 — Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment · Phase 3 · recruiting
NCT06252870 — Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-trans · Phase 2 · recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02151539 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 17 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02151539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing